ContraVir Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own ContraVir Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
189,269
1.31%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
96,535
0.67%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
44,203
0.31%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
23,050
0.16%
-1
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
18,614
0.13%
0
0%
07/31/2018
Vanguard Balanced Index Fund
9,201
0.06%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
4,647
0.03%
0
0%
09/06/2018
BlackRock Master Extended Market Index Series
2,250
0.02%
0
0%
01/31/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
1,687
0.01%
-1
0%
06/30/2018
Kaldi Capital, SICAV
0
0%
-438
0%
03/31/2018
| Address |
399 Thornall Street
Edison New Jersey 08837
United States
|
|
Employees
|
- |
| Website |
http://www.contravir.com |
| Updated |
07/08/2019 |
| ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ. |
